Oncternal Therapeutics, Inc. financial data

Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 06 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 400% % -57%
Debt-to-equity 35% %
Return On Equity -178% % -108%
Return On Assets -131% % -74%
Operating Margin -1664% % 75%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,959,645 shares -95%
Common Stock, Shares, Outstanding 2,960,000 shares -95%
Common Stock, Value, Issued $3,000 USD -95%
Weighted Average Number of Shares Outstanding, Basic 2,960,000 shares 0.41%
Weighted Average Number of Shares Outstanding, Diluted 2,960,000 shares 0.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,161,000 USD 228%
General and Administrative Expense $12,331,000 USD -3.4%
Operating Income (Loss) $35,959,000 USD 18%
Net Income (Loss) Attributable to Parent $34,575,000 USD 17%
Earnings Per Share, Basic -12 USD/shares 56%
Earnings Per Share, Diluted -12 USD/shares 56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,079,000 USD -12%
Assets, Current $15,447,000 USD -64%
Operating Lease, Right-of-Use Asset $154,000 USD -47%
Other Assets, Noncurrent $0 USD -100%
Assets $15,601,000 USD -64%
Accounts Payable, Current $1,198,000 USD -44%
Employee-related Liabilities, Current $592,000 USD -52%
Accrued Liabilities, Current $5,064,000 USD 77%
Liabilities, Current $6,453,000 USD 25%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $6,453,000 USD 4.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,000 USD
Retained Earnings (Accumulated Deficit) $223,190,000 USD -18%
Stockholders' Equity Attributable to Parent $9,148,000 USD -75%
Liabilities and Equity $15,601,000 USD -64%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,438,000 USD 32%
Net Cash Provided by (Used in) Financing Activities $87,000 USD -108%
Net Cash Provided by (Used in) Investing Activities $7,224,000 USD
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 2,960,000 shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $301,000 USD 99%
Operating Lease, Liability $191,000 USD -44%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $34,573,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid $200,000 USD -47%
Operating Lease, Liability, Current $191,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year Two $150,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $50,000 USD -74%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9,000 USD -75%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $232,334,000 USD 3%
Share-based Payment Arrangement, Expense $6,814,000 USD -3.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%